Skip to main content
Premium Trial:

Request an Annual Quote

GSK to Evaluate Aclara eTag Assays for Cancer Drug Development

NEW YORK, Oct. 5 (GenomeWeb News) - Aclara Biosciences said today that GlaxoSmithKline will evaluate Aclara's eTag assays for their potential use in patient selection for certain GSK targeted cancer therapies.

 

Under the terms of the agreement, GSK will provide Aclara with drug-treated biological samples, and Aclara will test the samples with eTag assays, Aclara said. The companies will then correlate biomarkers with response to the drug.

 

GlaxoSmithKline will provide funding to Aclara for the study, Aclara said, although it did not disclose specific financial details of the agreement.

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.